In the latest trading session, 0.41 million Alx Oncology Holdings Inc (NASDAQ:ALXO) shares changed hands as the company’s beta touched 1.04. With the company’s most recent per share price at $1.43 changed hands at -$0.05 or -3.04% at last look, the market valuation stands at $75.69M. ALXO’s current price is a discount, trading about -1146.85% off its 52-week high of $17.83. The share price had its 52-week low at $1.34, which suggests the last value was 6.29% up since then. When we look at Alx Oncology Holdings Inc’s average trading volume, we note the 10-day average is 0.84 million shares, with the 3-month average coming to 701.42K.
Analysts gave the Alx Oncology Holdings Inc (ALXO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ALXO as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Alx Oncology Holdings Inc’s EPS for the current quarter is expected to be -0.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Alx Oncology Holdings Inc (NASDAQ:ALXO) trade information
Instantly ALXO was in red as seen in intraday trades today. With action -5.59%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -90.36%, with the 5-day performance at -5.59% in the red. However, in the 30-day time frame, Alx Oncology Holdings Inc (NASDAQ:ALXO) is -7.42% down. Looking at the short shares, we see there were 9.59 million shares sold at short interest cover period of 19.5 days.
The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need an upside of 93.78% from its recent market value. According to analyst projections, ALXO’s forecast low is 14 with 38 as the target high. To hit the forecast high, the stock’s price needs a -2557.34% plunge from its current level, while the stock would need to soar -879.02% for it to hit the projected low.
Alx Oncology Holdings Inc (ALXO) estimates and forecasts
Data shows that the Alx Oncology Holdings Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -90.54% over the past 6 months, a 21.66% in annual growth rate that is considerably higher than the industry average of 17.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -50.98%. The 2024 estimates are for Alx Oncology Holdings Inc earnings to increase by 25.36%.
ALXO Dividends
Alx Oncology Holdings Inc is expected to release its next quarterly earnings report on 2025-Mar-05.
Alx Oncology Holdings Inc (NASDAQ:ALXO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.91% of Alx Oncology Holdings Inc shares while 107.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.07%. There are 107.96% institutions holding the Alx Oncology Holdings Inc stock share, with VENBIO PARTNERS LLC the top institutional holder. As of 2024-06-30, the company held 19.3531% of the shares, roughly 9.7 million ALXO shares worth $58.49 million.
FMR LLC holds the second largest percentage of outstanding shares, with 15.5923% or 7.81 million shares worth $47.12 million as of 2024-06-30.
